Navigation Links
Preparative Nondenaturing Gel Electrophoresis Used in the Purification of an Esterase Involved in Insecticide Resistance, Rev C

Dr Albert J Ketterman and SHP Parakrama Karunaratne, Dept. of Medical Parasitology, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT UK


Introduction

In attempts to control Culex quinquefasciatus as a worldwide vector of diseases such and filariasis and encephalitis, mosquito field populations are sprayed with organophosphate insecticides. However, mosquitoes develop tolerance to organophosphate.

One of the mechanisms of organophosphate resistance involves either a different form and/or increased amounts in a carboxyolesterase (EC 3.1.1.1). Carboxylesterase A2 is one of two enzymes found elevated together in Culex mosquitoes. The putative mechanism involving the resistance-conferring carboxylesterase A2 is an increased expression in this enzyme for the sequestration of, and cross-resistance to, various organophosphate and carbamate insecticides (Raymond et al. 1991).

The question of a qualitative change in the carboxylesterase has not been fully explored with a purified enzyme. Here we report the use of Bio-Rads Model 491 prep cell for preparative, nondenaturing gel electrophoresis as a final step in purifying the native carboxylesterase A2.


Methods
Carboxylesterase A2 was isolated from the supernatant of a mosquito homogenate by sequential ion exchange, hydrophobic interaction, and hydroxyapatite chromatography, followed by a final purification step using the Model 491 prep cell (Ketterman et al. 1992).

Preparative Native PAGE
As suggested in the Model 491 prep cell instruction manual, the gel composition (monomer concentration) for maximum resoluti
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF
2. Detection of Platinum Species in Plant Material by Preparative Isotachophoresis Using the Model 491 Prep Cell, Rev A
3. Preparative Nondenaturing Gel Electrophoresis to Purify NADP-Specific Glutamate Dehydrogenase From Chlorella, Rev B
4. Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C
5. Purification and Characterization of beta-Lactoglobulin Genetic Variants A and B Using Preparative Electrophoresis and Isoelectric Focusing
6. A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF
7. Semi Preparative Purification of Proteins
8. A Versatile Power Supply for All Electrophoresis Applications
9. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
10. Continuous-Elution Electrophoresis for Purification of the Baculovirus-Expressed Coronavirus Structural Proteins, Rev A
11. Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System
Post Your Comments:
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4
Other Biology Technology:measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 2measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 3measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 4measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 5measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 6measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 7measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 8measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 9measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 10measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 11measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 12measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 13measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 14measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 15Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 2Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 3Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 4Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 5Protocol for GenomePlex Whole Genome Amplification from Plant 2Protocol for GenomePlex Whole Genome Amplification from Plant 3Protocol for GenomePlex Whole Genome Amplification from Plant 4Protocol for GenomePlex Whole Genome Amplification from Plant 5Protocol for GenomePlex Whole Genome Amplification from Plant 6
Breaking Biology News(10 mins):Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Successful stem cell therapy for treatment of eye disease 2Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 1Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 1Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 2Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 4Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 5Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 6Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 7Regences Social Media Web Site Gets a Facelift 60731 1Regences Social Media Web Site Gets a Facelift 60731 2